v3.26.1
Document and Entity Information
 12 Months Ended
Mar. 31, 2026
shares
Document Information [Line Items]  
Document Type 20-F
Amendment Flag false
Document Period End Date Mar. 31, 2026
Document Fiscal Year Focus 2026
Document Fiscal Period Focus FY
Entity Registrant Name Virax Biolabs Group Limited
Entity Central Index Key 0001885827
Entity Current Reporting Status Yes
Entity Voluntary Filers No
Entity Interactive Data Current Yes
Current Fiscal Year End Date --03-31
Entity Filer Category Non-accelerated Filer
Entity Well-known Seasoned Issuer No
Entity Common Stock, Shares Outstanding 579,218
Entity Shell Company false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity File Number 001-41440
Entity Incorporation, State or Country Code E9
Entity Address, Address Line One BioCity Glasgow
Entity Address, Address Line Two Bo’Ness Road Newhouse
Entity Address, City or Town Lanarkshire
Entity Address, Postal Zip Code ML1 5UH
Entity Address, Country GB
Document Annual Report true
Document Transition Report false
Document Shell Company Report false
Document Registration Statement false
Document Accounting Standard International Financial Reporting Standards
ICFR Auditor Attestation Flag false
Document Financial Statement Error Correction [Flag] false
Auditor Name Reliant CPA PC
Auditor Firm ID 6906
Auditor Location Newport Beach, CA
Trading Symbol VRAX
Title of 12(b) Security ordinary shares, par value $0.025 per share
Security Exchange Name NASDAQ
Auditor Opinion

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated statements of financial position of Virax Biolabs Group Limited (the “Company”), as of March 31, 2026 and 2025, the related consolidated statements of loss and comprehensive loss, changes in shareholders’ equity and cash flows for each of the three years in the period ended March 31, 2026, and related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2026 and 2025, and the results of its operations and its cash flows for each of the three years in the period ended March 31, 2026, in conformity with the International Financial Reporting Standards as issued by the International Accounting Standards Board.
Business Contact  
Document Information [Line Items]  
Entity Address, Address Line One BioCity Glasgow
Entity Address, Address Line Two Bo’Ness Road Newhouse
Entity Address, City or Town Lanarkshire
Entity Address, Postal Zip Code ML1 5UH
Entity Address, Country GB
City Area Code +44 020
Local Phone Number 7788 7414
Contact Personnel Name James Foster
Contact Personnel Email Address info@viraxbiolabs.com